Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Int J Biochem Cell Biol. 2011 Apr;43(4):474-7. doi: 10.1016/j.biocel.2011.01.005. Epub 2011 Jan 15.

Enhancer of zeste homolog 2: A potential target for tumor therapy.

Author information

  • College of Life Sciences, Zhejiang University, 388 Yuhangtang Road, Hangzhou, Zhejiang Province, 310058, PR China. ytxiaocell@163.com

Abstract

Enhancer of zeste homolog 2 (EZH2) is a subunit of the Polycomb-Repressive Complex 2 (PRC2), which catalyses the trimethylation of histone H3 on Lys 27 (H3K27) and involves in genes repression. EZH2 is amplified and overexpressed in a variety of cancers, including prostate and breast cancer. Overexpression of EZH2 has been associated with the invasion and progression of malignant cancers, especially with the progression of prostate cancer. Here, we review the structure and biological function of EZH2, especially focused on its activities in the tumorigenesis.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID:
21241820
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk